Exosome treatment for KRAS-mutated metastatic pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This Phase 1/2 study tests an investigational treatment made from “exosomes” for people with metastatic pancreatic cancer that has a specific KRAS mutation (KRAS G12D). It aims to see if this treatment can control the cancer and is safe for patients whose cancer has grown or stayed the same after prior chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic pancreatic ductal adenocarcinoma confirmed by pathology (biopsy/surgery).
- Your tumor has the KRAS G12D mutation from prior testing, or you can have it re-checked before starting.
- Your cancer must have progressed, or stayed stable, after one or more prior chemotherapy treatments (if it stayed stable, you must have had at least 4 months of chemo).
- Your overall health score (ECOG) must be 0 or 1, meaning you’re able to carry out most daily activities.
- Your blood counts and organ tests must be within study limits (white blood cells, platelets, hemoglobin, kidney and liver numbers).
- You are not pregnant or breastfeeding, and you (or your partner, if applicable) use reliable birth control during the study and for up to 12 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a lab-made immune cell (T-cell) treatment that targets a specific KRAS mutation (G12V) found in some pancreatic cancers. It may help shrink tumors or control cancer growth after standard treatment, and it mainly focuses on safety and early effectiveness.
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial tests a new medicine (DN022150) combined with standard chemotherapy as a first treatment for advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The combination may help shrink or slow the cancer better than chemotherapy alone.
This trial tests a new experimental drug, RNK08954, for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and can help shrink or slow the cancer.
This trial tests a new vaccine that targets KRAS mutations in patients with colorectal or pancreatic cancer after surgery and chemotherapy. The goal is to see if the vaccine can help prevent the cancer from coming back.
Hear when a new Metastatic Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.